353 related articles for article (PubMed ID: 15719595)
1. Aromatase inhibitors in advanced breast cancer.
Mouridsen HT
Semin Oncol; 2004 Dec; 31(6 Suppl 12):3-8. PubMed ID: 15719595
[TBL] [Abstract][Full Text] [Related]
2. Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer.
Riemsma R; Forbes CA; Kessels A; Lykopoulos K; Amonkar MM; Rea DW; Kleijnen J
Breast Cancer Res Treat; 2010 Aug; 123(1):9-24. PubMed ID: 20535542
[TBL] [Abstract][Full Text] [Related]
3. The role of aromatase inhibitors in the treatment of metastatic breast cancer.
Mouridsen H; Gershanovich M
Semin Oncol; 2003 Aug; 30(4 Suppl 14):33-45. PubMed ID: 14513435
[TBL] [Abstract][Full Text] [Related]
4. Letrozole: a review of its use in postmenopausal women with breast cancer.
Simpson D; Curran MP; Perry CM
Drugs; 2004; 64(11):1213-30. PubMed ID: 15161328
[TBL] [Abstract][Full Text] [Related]
5. A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.
Rose C
Am J Clin Oncol; 2003 Aug; 26(4):S9-16. PubMed ID: 12902872
[TBL] [Abstract][Full Text] [Related]
6. Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer.
Mouridsen HT; Robert NJ
MedGenMed; 2005 Aug; 7(3):20. PubMed ID: 16369246
[TBL] [Abstract][Full Text] [Related]
7. Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.
Dunn C; Keam SJ
Pharmacoeconomics; 2006; 24(5):495-517. PubMed ID: 16706574
[TBL] [Abstract][Full Text] [Related]
8. Aromatase inhibitors in early breast cancer therapy.
Smith IE
Semin Oncol; 2004 Dec; 31(6 Suppl 12):9-14. PubMed ID: 15719596
[TBL] [Abstract][Full Text] [Related]
9. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on letrozole or anastrozole. A phase II trial conducted by the Hellenic Group of Oncology (HELGO).
Gennatas C; Michalaki V; Carvounis E; Psychogios J; Poulakaki N; Katsiamis G; Voros D; Kouloulias V; Mouratidou D; Tsavaris N
Tumori; 2006; 92(1):13-7. PubMed ID: 16683378
[TBL] [Abstract][Full Text] [Related]
10. The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors.
Rugo HS
Ann Oncol; 2008 Jan; 19(1):16-27. PubMed ID: 17693420
[TBL] [Abstract][Full Text] [Related]
11. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
Berry J
Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
[TBL] [Abstract][Full Text] [Related]
12. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
13. The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer.
Hamilton A; Piccart M
Ann Oncol; 1999 Apr; 10(4):377-84. PubMed ID: 10370778
[TBL] [Abstract][Full Text] [Related]
14. Role of anti-aromatase agents in postmenopausal advanced breast cancer.
Murray R
Cancer Chemother Pharmacol; 2001 Oct; 48(4):259-65. PubMed ID: 11710624
[TBL] [Abstract][Full Text] [Related]
15. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer.
Bertelli G; Garrone O; Merlano M; Occelli M; Bertolotti L; Castiglione F; Pepi F; Fusco O; Del Mastro L; Leonard RC
Oncology; 2005; 69(6):471-7. PubMed ID: 16410685
[TBL] [Abstract][Full Text] [Related]
16. Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial.
Llombart-Cussac A; Ruiz A; Antón A; Barnadas A; Antolín S; Alés-Martínez JE; Alvarez I; Andrés R; García Saenz JA; Lao J; Carrasco E; Cámara C; Casas I; Martín M
Cancer; 2012 Jan; 118(1):241-7. PubMed ID: 21717449
[TBL] [Abstract][Full Text] [Related]
17. Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.
Glück S
Am J Clin Oncol; 2010 Jun; 33(3):314-9. PubMed ID: 19730353
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumor effects of letrozole.
Miller WR; Anderson TJ; Dixon JM
Cancer Invest; 2002; 20 Suppl 2():15-21. PubMed ID: 12442345
[TBL] [Abstract][Full Text] [Related]
19. Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy?
Sainsbury R
Br J Cancer; 2004 May; 90(9):1733-9. PubMed ID: 15150604
[TBL] [Abstract][Full Text] [Related]
20. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
Marchetti M; Caruggi M; Colombo G
Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
